Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Media

The FT, Sky News, Bloomberg, WSJ, along with over 77 other leading press organisations worldwide quote our data and insight and consider us a trusted, independent source.

Top 20 global payment companies’ revenue grows by 9% in 2024 as market sees structural shifts, says GlobalData

In 2024, the global payment ecosystem witnessed structural changes with digital acceleration, consumer behavior shifts, and macroeconomic pressures reshaping the industry landscape. The top 20 publicly listed payment companies by revenue have navigated this landscape with varying degrees of agility, innovation, and strategic execution. The top 20 public payment companies saw their revenues rise by […]
Read more

EyePoint’s Duravyu holds potential to become new treatment option for wAMD, says GlobalData

EyePoint Pharmaceuticals’ Duravyu (vorolanib) is in the spotlight following its recent advancements in its Phase III trial. The company recently announced the completion of patient enrollment for LUGANO, its pivotal Phase III clinical trial. The current wet age-related macular degeneration (wAMD) treatment landscape is largely dominated by vascular endothelial growth factor (VEGF) inhibitors. Duravyu is […]
Read more

UAE’s power capacity to reach 79.1GW in 2035, forecasts GlobalData

The United Arab Emirates (UAE) boasts one of the most secure and stable electricity supply systems in the region. Leveraging its substantial natural gas and oil reserves, among the largest globally, the UAE generates sufficient electricity to satisfy domestic consumption. The nation primarily utilizes its gas for power generation and for re-injection into oil fields […]
Read more

Enterprises need to jump on opportunities presented by global AI sovereignty strategies, says GlobalData

AI is no longer simply a competitive differentiator for enterprises; the technology is increasingly critical to national security and economic empowerment, prompting countries across the globe to implement strategies that support AI sovereignty. While narrowly defined by some as a focus primarily on infrastructure, AI sovereignty should include a broad swath of capabilities that relate […]
Read more

UK biopharma venture financing QoQ doubles to $1.1 billion in Q1 2025, reveals GlobalData

UK biopharmaceutical companies experienced a quarter-on-quarter (QoQ) surge in venture financing, reaching $1.1 billion in the first quarter (Q1) of 2025—twice the amount raised in the fourth quarter (Q4) of 2024 and exceeding all quarterly totals from 2021. This surge highlights investor appetite for breakthrough innovation, but growing dependence on US capital and policy-driven cost […]
Read more

CAR-T therapies need to overcome current limitations to unlock promising treatment possibilities for solid tumors, says GlobalData

CAR-Ts are revolutionizing the treatment of blood cancers, such as B-cell acute lymphocytic leukemia. However, their success has not yet extended to the realm of solid tumors, as no CAR-T therapy has advanced beyond Phase II in one of these indications. Overcoming current limitations and expanding the reach of CAR-T therapeutics could unlock promising new […]
Read more

Sibeprenlimab’s priority review highlights potential to differentiate in IgAN space, says GlobalData

Otsuka Pharmaceutical recently announced that the FDA has accepted for review the Biologics License Application (BLA) for sibeprenlimab, which acts as A Proliferation Inducing Ligand (APRIL) inhibitor in development for immunoglobulin A (IgA) nephropathy (IgAN). This followed sibeprenlimab’s 2024 FDA breakthrough designation for the same indication. The BLA was supported by the Phase III VISIONARY […]
Read more

Audi YouTube ads blend performance with purpose, emphasizing electric mobility and social responsibility, reveals GlobalData

Audi AG’s (Audi) YouTube advertising campaigns from November 2024 to April 2025 spotlight its growing commitment to electric mobility models ranging from the Quattro all-wheel drive system to A6 e-tron and Q6 e-tron. The ads blend high performance with sustainability, reflecting the Germany-based automotive giant’s aim to meet the needs of today’s luxury buyers who […]
Read more

Global renewable power installed capacity to surge to 11.2TW by 2035, forecasts GlobalData

The power sector is experiencing a notable growth in renewable energy sources, propelled by an array of factors such as technological progress, policy incentives, and a heightened awareness of the imperative for sustainable energy solutions. Consequently, renewable resources, particularly solar photovoltaic (PV) and wind energy, are gaining a larger share in the energy portfolio. Driven […]
Read more

Deforestation now poses material risk as EUDR enforces strict supply chain accountability, says GlobalData

Deforestation is no longer just a reputational concern, it is now a material risk with regulatory teeth. With the EU Deforestation Regulation (EUDR) taking effect in December 2025, companies across sectors must prove their supply chains are deforestation-free or face severe penalties. The shift demands urgent action on traceability, supplier engagement, and sustainability strategy to […]
Read more

Kazakhstan’s electricity consumption to increase to 111TWh by 2035, forecasts GlobalData

Kazakhstan’s electricity consumption has been on a steady rise, driven by industrial expansion, urbanization, digitalization, and electrification. The nation’s power demand is predominantly fueled by energy-intensive industries, mining, oil and gas operations, and residential sector growth. This surge in industrial activity has led to a heightened demand for electricity; annual consumption escalated from 83.9TWh in […]
Read more

China’s biopharma commands $30 billion in oncology licensing deals, triples US output in 2024, reveals GlobalData

China’s biopharmaceutical sector experienced a notable increase in oncology drug licensing deals in 2024, particularly for monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), with a combined deal value of $30 billion. The mAbs and ADCs licensed from Chinese biopharma accounted for 89% of all molecule types, with the total deal value being three times that […]
Read more

GlobalData forecasts ADC NSCLC market to reach $3.9 billion in 2032

Despite the FDA first approving Pfizer’s antibody-drug conjugate (ADCs) Mylotarg (gemtuzumab ozogamicin) in 2000, it was not until 2022 for non-small-cell lung cancer (NSCLC) to see its first ADC approval, AstraZeneca’s and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), for human epidermal growth factor receptor (HER) 2-mutated patients. Following this approval, the ADC market in NSCLC is […]
Read more
1 … 62 63 64 65 66 … 773